On June 22, 2026, the U.S. Department of Health and Human Services (HHS) announced the launch of Operation TrialBlazer, a coordinated effort ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

The US Food and Drug Administration (FDA) and the medtech industry have agreed to commitment letter language for the Medical ...

Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy; Immuron is seeking a partner to support clinical development through regulatory approval and ...

The tailor-made comprehensive offering spans a diversified clinical and commercial portfolio of innovative modalities, ...

Henny Zijlstra, Chief Commercial Officer of Ardena, discusses the integrated CDMO model, Ardena’s new laboratory in New ...

The US Food and Drug Administration (FDA) revised its compliance program guide (CPG) for preapproval inspections (PAIs) for new drugs. This update emphasizes a risk-based approach to making decisions ...

Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy July 7, 2026 4:30 PM EDTCompany ParticipantsSean Grant ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

“Major brands like Grupo Bimbo, General Mills, Kraft Heinz and many more have made public commitments to eliminate artificial colors from their product portfolios,” Jones said. “Brands are ...

Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle™ Platform ...

Artificial intelligence (AI) is quickly becoming a key factor for life sciences companies. In addition to improving efficiency and ...